The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has rejected subsidy for the obesity medication Wegovy, according to reports. This decision means patients will need to continue paying for the weight loss drug themselves. Novo Nordisk, the manufacturer of Wegovy, had been negotiating with regional health authorities and TLV since spring about potential subsidy arrangements, but the agency ultimately said no to public funding.
The rejection comes amid growing demand for weight loss medications in Sweden, with Wegovy being one of the most popular options alongside Mounjaro Kwikpen. 8 million kronor were purchased in 2025, indicating significant patient interest despite the lack of public subsidy. Medical professionals have noted both the benefits and risks of these new weight loss treatments, emphasizing that they require ongoing medical supervision rather than being one-time interventions.